Vericel Corp
NASDAQ:VCEL

Watchlist Manager
Vericel Corp Logo
Vericel Corp
NASDAQ:VCEL
Watchlist
Price: 38.08 USD -2.71% Market Closed
Market Cap: $1.9B

Net Margin

5.1%
Current
Improving
by 6.7%
vs 3-y average of -1.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
5.1%
=
Net Income
$13.1m
/
Revenue
$258.7m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
5.1%
=
Net Income
$13.1m
/
Revenue
$258.7m

Peer Comparison

Country Company Market Cap Net
Margin
US
Vericel Corp
NASDAQ:VCEL
2B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
55th
Based on 15 072 companies
55th percentile
5.1%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Vericel Corp
Glance View

Market Cap
1.9B USD
Industry
Biotechnology

Vericel Corporation, nestled in the bustling hub of biomedical innovation in Cambridge, Massachusetts, has carved out a niche in the realm of advanced cell therapies. Founded in the late 1980s, the company initially focused on regenerative medicine but has since honed its expertise on the development and commercialization of cell-based treatments for patients with serious medical conditions. Vericel's journey is underpinned by its flagship product lines like MACI® and Epicel®, which illustrate its commitment to technological advancement and improving patient outcomes. MACI®, a matrix-applied autologous cultured chondrocyte technology, is designed to repair cartilage defects in the knee, often providing relief to those who suffer chronic pain from cartilage injuries. Epicel®, on the other hand, caters to patients with severe burns, utilizing a patient's own skin cells to regenerate skin and improve healing. These innovative solutions demonstrate Vericel's strategic pivot towards addressing niche, high-need areas within the orthopedic and burn treatment spaces. Vericel makes its revenue primarily through the sales of its proprietary treatments to hospitals and healthcare providers. The company's growth is closely tied to its ability to navigate the intricate regulatory landscapes associated with biologics, ensuring that its therapies meet the stringent requirements set forth by entities like the FDA. By targeting specific, high-impact markets with limited existing solutions, Vericel secures a competitive edge and commands significant pricing power, which enhances its financial performance. The company invests heavily in clinical trials and research to support and expand the use of its technologies, seeking indications for broader patient populations. Additionally, Vericel is continually working to optimize its manufacturing processes to scale its operations effectively without compromising the quality and efficacy of its treatments. Through strategic partnerships and a focus on innovation, Vericel is poised to leverage its scientific expertise to further entrench its position within the specialized markets it serves.

VCEL Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
5.1%
=
Net Income
$13.1m
/
Revenue
$258.7m
What is Vericel Corp's current Net Margin?

The current Net Margin for Vericel Corp is 5.1%, which is above its 3-year median of -1.6%.

How has Net Margin changed over time?

Over the last 3 years, Vericel Corp’s Net Margin has increased from -11.4% to 5.1%. During this period, it reached a low of -11.4% on Aug 30, 2022 and a high of 5.1% on Oct 30, 2025.

Back to Top